Platforms for long acting non-viral gene therapy for ocular diseases
Eyevensys has raised €45M across 5 funding rounds from 5 investors, most recently a Series B round in Aug 2021. Based in Paris, France; founded 2008; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-08-09 | Series B | €10M | Korea Investment Partners | View deal → |
| 2020-08-01 | Series B | €25M | Boehringer Ingelheim Venture Fund | View deal → |
| 2016-09-01 | Series A | €9.0M | Pontifax Funds | View deal → |
| 2015-06-01 | Seed | €0 | CapDecisif Management,Inserm Transfert Initiative | View deal → |
| 2013-04-01 | Early VC | €0 | Boehringer Ingelheim Venture Fund | View deal → |
